Teva CEO Says Company Aims to Grow in 2027 Despite IRA Impact
Teva CEO Francis said the company aims to grow in 2027 despite the US Inflation Reduction Act’s impact on its Austedo drug.
Related stories
Unidata Sees 2026 Revenue of €110M–€111M, Down 3–4% From Prior Guidance
M impact | EARNINGS | Nov 03, 2026, 03:55 PM UTC
Fiserv Rises After Announcing Job Cuts and Beating Quarterly Forecasts
Fiserv shares rose after the company announced workforce cuts and exceeded quarterly forecasts.
M impact | EARNINGS | Nov 03, 2026, 03:55 PM UTC
ADM dépasse les prévisions trimestrielles et relève ses prévisions de bénéfice annuel
ADM a dépassé les prévisions trimestrielles et relevé ses prévisions de bénéfice annuel, grâce à des marges de transformation plus élevées.
M impact | EARNINGS | Nov 03, 2026, 03:53 PM UTC
Pfizer raises 2026 outlook as third-quarter sales grow
Pfizer raised its 2026 performance outlook, citing third-quarter growth from Eliquis and cancer medicines. Eliquis sales rose 25%. Cecile Guegan was named chief financial officer.
M impact | EARNINGS | Nov 03, 2026, 03:52 PM UTC
Unidata reports 9M 2026 revenue of €81.10 million
M impact | EARNINGS | Nov 03, 2026, 03:52 PM UTC
Pfizer Raises 2026 Forecasts on Third-Quarter Results
Pfizer said Eliquis and cancer drugs drove its third-quarter results. The headline reports higher 2026 forecasts but provides no figures.
M impact | EARNINGS | Nov 03, 2026, 03:52 PM UTC